clinical trial · NCT07106762
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb·phase3·recruiting·n = 470
Urothelial CancerIza-brenCisplatinGemcitabineCarboplatin
brief summary
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
started
Sep 30, 2025
primary completion
Jan 26, 2029
completion
Nov 18, 2033
last updated
Apr 15, 2026
official title
IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol